To be added to the scientific events notification list, please click here.
My laboratory studies how the chromatin microenvironment regulates gene expression while maintaining a stable genome. We have initiated these types of studies by focusing on a specific class of chromatin regulators, JmjC-containing histone demethylases. Since their discovery, my laboratory has been screening both solid and hematopoietic cancer for genomic anomalies in this class of enzymes. We have uncovered the first enzyme (KDM4A- histone tri-demethylase) responsible for generating site-specific DNA copy gain and are addressing the genomic features that are responsible for increasing the propensity of these regions to copy gain and rereplication during S phase. We are evaluating these aspects in tumors that have altered copy number and develop drug resistance. Our findings have prompted us to interrogate these same relationships with other chromatin/epigenetic modifiers (e.g., lysine methyltransferases and demethylases) and tumors drug response as well. Our discoveries have significant implications in understanding tumor copy number heterogeneity and drug response across cancers. These studies will be discussed during my seminar.
For more information regarding Dr. Whetstine, please visit: https://www.foxchase.org/johnathan-whetstine
Johnathan Whetstine, Ph.D.
Institute for Cancer Research
Fox Chase Cancer Center
12:00 pm at Van Andel Institute
Conference Room 3104/3105
For questions, please contact Kim Cousineau at 616.234.5684.